The DNA sequence coming from the PCSK9 monoclonal antibody produced from the synthesized human PCSK9 peptide immunization was cloned into the expression vector, which was further transfected into a cell line for in vitro expression. The product is the recombinant PCSK9 monoclonal antibody. It specifically targets the PCSK9 from human. It belongs to the rabbit IgG. The affinity-chromatography purification method was used to purify this PCSK9 antibody. The ELISA, WB, and IHC analyses have been tested for this PCSK9 antibody.
The dyslipidemia treatment based on PCSK9 monoclonal antibodies is currently recommended to achieve risk-specific low-density lipoprotein cholesterol (LDL-C) goal to reduce adverse cardiovascular (CV) events. Two fully human anti-PCSK9 antibodies evolocumab and alirocumab developed by transgenic mice platforms have been approved for hypercholesterolemia treatment in the clinical.
Hide more
